Share Price:

APNASPENAspen Pharmacare Hldgs2324952 (0.22%)

Aspen is in a closed period from 1st July 2024 until the publication of the FY2024 results on the JSE SENS platform to be released on the 3rd September 2024.

Investor Relations

Investor Hub

We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality, affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.

Stephen Saad

Group Chief Executive

Our business strategy is to create value for our stakeholders by promoting access to medicines through building robust product portfolios that achieve organic growth and by leveraging our world-class manufacturing capacities and capabilities. We seek to achieve this by building a differentiated portfolio of relevant IP, creating value through our complex manufacturing capabilities and enabling access through our globally integrated supply chain.

Our market positioning is focused on opportunities presented by emerging markets, balanced with presence in more established, stable developed markets. Through our dynamic portfolio management model, we build, optimise and reshape our basket of products to achieve a global product portfolio of niche, specialty products complemented by leading regional brands, aligned to our manufacturing capability.

We have proven manufacturing capability and capacity, creating access and sustainability collaboration opportunities for multinationals.

Firm Analyst Contact Details

Covering analyst

HSBC

Raj Sinha

raj.sinha@hsbc.com

Covering analyst

Investec

Letlotlo Lenake

letlotlo.lenake@investec.co.za

Covering Analyst

JPM

Alex Comer

alex.r.comer@jpmorgan.com

Covering analyst

Nedbank

Luyanda Njilo

luyandan@nedbank.co.za

Covering Analyst

RMBMS

Roy Campbell

roy.campbell@rmbmorganstanley.com

Covering analyst

Standard Bank

Anuja Joshi

anujajoshi@sbgsecuritiescom

Latest Results: H1 2024

Revenue increased by 10%
(2% CER) to
R 0 ,1 billion

December 2022: R19,2 billion

Normalised EBITDA increased by 2% (-5% CER) to
R 0 ,2 billion

December 2022: R5,1 billion

Normalised headline earnings per share increased by 1% (-5% in CER) to
6 0 cents

December 2022: 679,6 cents

Operating cash flow per share increased by 44% to
5 0 cents

December 2022: 384,3 cents

Dividend declared to shareholders increased by 5% to
0 cents per ordinary share

June 2022: 326 cents

Financial Results and Presentations

Interim Results



Additional Presentations and webcasts

Annual Results

 

Interim Results

Annual Results

 

Interim Results

Annual Results



Interim Results



Additional Presentations and Webcasts

Integrated Reporting

Integrated Reporting Suite

 

Supplementary Documents

Integrated Reporting Suite

 

Supplementary Documents

Integrated Reporting Suite

 

Supplementary Documents

Integrated Reporting Suite

 

Supplementary Documents

Share Price Information

Financial Calendar

Error: Unable to load XML feed.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.